That might be a viable explanation -- except for the fact that I doubt the DSMC, nor especially the FDA, would provide CytoDyn with the guarantee that they would be finished reviewing the data and have a final conclusion by 4pm on Tuesday.

SEC regulations demand material events be disclosed within four business days. The Tuesday call lines-up nicely in this context.